Immunotherapy for hepatocellular carcinoma: Current and future
Immunotherapy for hepatocellular carcinoma: Current and future
Hepatocellular carcinoma (HCC) arises on the background of chronic liver disease. Despite the development of effective anti-viral therapeutics HCC is continuing to rise, in part driven by the epidemic of non-alcoholic fatty liver disease. Many patients present with advanced disease out with the criteria for transplant, resection or even locoregional therapy. Currently available therapeutics for HCC are effective in a small minority of individuals. However, there has been a major global interest in immunotherapies for cancer and although HCC has lagged behind other cancers, great opportunities now exist for treating HCC with newer and more sophisticated agents. Whilst checkpoint inhibitors are at the forefront of this revolution, other therapeutics such as inhibitory cytokine blockade, oncolytic viruses, adoptive cellular therapies and vaccines are emerging. Broadly these may be categorized as either boosting existing immune response or stimulating de novo immune response. Although some of these agents have shown promising results as monotherapy in early phase trials it may well be that their future role will be as combination therapy, either in combination with one another or in combination with treatment modalities such as locoregional therapy. Together these agents are likely to generate new and exciting opportunities for treating HCC, which are summarized in this review.
Adoptive cell therapy, Cancer vaccine, Checkpoint inhibitor, Hepatocellular carcinoma, Immunotherapy, Liver cancer, Oncolytic virus
2977-2989
Johnston, Michael P.
50f7f267-8e9e-497c-84dd-15f905b9419d
Khakoo, Salim I.
6c16d2f5-ae80-4d9b-9100-6bfb34ad0273
Johnston, Michael P.
50f7f267-8e9e-497c-84dd-15f905b9419d
Khakoo, Salim I.
6c16d2f5-ae80-4d9b-9100-6bfb34ad0273
Johnston, Michael P. and Khakoo, Salim I.
(2019)
Immunotherapy for hepatocellular carcinoma: Current and future.
World Journal of Gastroenterology, 25 (24), .
(doi:10.3748/wjg.v25.i24.2977).
Abstract
Hepatocellular carcinoma (HCC) arises on the background of chronic liver disease. Despite the development of effective anti-viral therapeutics HCC is continuing to rise, in part driven by the epidemic of non-alcoholic fatty liver disease. Many patients present with advanced disease out with the criteria for transplant, resection or even locoregional therapy. Currently available therapeutics for HCC are effective in a small minority of individuals. However, there has been a major global interest in immunotherapies for cancer and although HCC has lagged behind other cancers, great opportunities now exist for treating HCC with newer and more sophisticated agents. Whilst checkpoint inhibitors are at the forefront of this revolution, other therapeutics such as inhibitory cytokine blockade, oncolytic viruses, adoptive cellular therapies and vaccines are emerging. Broadly these may be categorized as either boosting existing immune response or stimulating de novo immune response. Although some of these agents have shown promising results as monotherapy in early phase trials it may well be that their future role will be as combination therapy, either in combination with one another or in combination with treatment modalities such as locoregional therapy. Together these agents are likely to generate new and exciting opportunities for treating HCC, which are summarized in this review.
Text
WJG-25-2977
- Version of Record
More information
Accepted/In Press date: 18 May 2019
e-pub ahead of print date: 28 June 2019
Keywords:
Adoptive cell therapy, Cancer vaccine, Checkpoint inhibitor, Hepatocellular carcinoma, Immunotherapy, Liver cancer, Oncolytic virus
Identifiers
Local EPrints ID: 432853
URI: http://eprints.soton.ac.uk/id/eprint/432853
ISSN: 1007-9327
PURE UUID: 7b1eac11-6c95-40bd-a42f-f4f19fb615b8
Catalogue record
Date deposited: 31 Jul 2019 16:30
Last modified: 16 Mar 2024 03:25
Export record
Altmetrics
Contributors
Author:
Michael P. Johnston
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics